NRAS G12V clinical trials at University of California Health

2 in progress, 1 open to eligible people

Showing trials for

  • First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

    open to eligible people ages 18 years and up

    This is a Phase 1 first-in-human, open-label multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of RLY-8161, an NRAS-selective inhibitor, in participants with advanced NRAS-mutant melanoma and other solid tumors.

    at UCLA

  • ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

    Sorry, in progress, not accepting new patients

    This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides 7P]) as adjuvant treatment in subjects with solid tumors with mutated KRAS/NRAS. This study builds on the experience obtained with related product ELI-002 2P, which was studied in protocol ELI-002-001 under IND 26909.

    at UC Irvine UCLA

Last updated: